June 2026 Quarterly Activities Report and Appendix 4C
Filed with ASX · · 12 pages · English
In the deck
Story so far
Earlier from Racura Oncology
- Bellberry Ethics Approval Activates New HARNESS Trial Sites
- Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
- Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
- Racura raised $34.3m to Advance Three Oncology Trials
- Emerging Companies Specialist Invests in Racura
Later from Racura Oncology
- First HARNESS-1 Patient Safely Treated with RC220
- CPACS Trial Opens for RC220 Patient Enrolment in Korea
- HARNESS-1 First Cohort Cleared
- Sept 2026 Quarterly Activities Report and Appendix 4C
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology